Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects

NCT01313962 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

DRUG: Flufirvitide-3 0.05 mg single dose
DRUG: Flufirvitide-3, 0.1 mg single dose
DRUG: Flufirvitide-3, 0.2 mg single dose
DRUG: Flufirvitide-3, 0.4 mg single dose
OTHER: Placebo

Sponsor

Autoimmune Technologies, LLC